Jaguar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on July 24, 2019. The report details corporate governance actions taken at the annual stockholder meeting on May 24, 2019, and by the Board of Directors on July 19, 2019, which became effective on the "Calculation Date" of July 24, 2019.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on equity plan amendments and stock option grants.
Material Changes
- 2014 Stock Incentive Plan Amendment: Stockholders approved an amendment to increase the authorized shares available for issuance under the 2014 Plan to 12.5% of the fully diluted outstanding shares as of the Calculation Date.
- Share Count Impact: As of July 24, 2019, the total fully diluted shares were 30,404,653, resulting in 4,330,400 shares authorized for issuance under the plan.
- Stock Option Grants: The Board approved grants to Executive Officers effective July 24, 2019, with an exercise price of $1.73 per share (closing price on July 23, 2019).
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of risks and contingencies. It is a procedural report regarding equity compensation.
Important Facts for Investors to Verify
- Executive Option Grants:
- Lisa Conte (CEO): 1,042,052 total shares (144,729 vested immediately; 897,323 vesting monthly over 36 months).
- Steven R. King (EVP): 347,351 total shares (48,243 vested immediately; 299,108 vesting monthly over 36 months).
- Karen S. Wright (CFO): 303,932 total shares (31,172 vested immediately; 272,760 vesting monthly over 36 months).
- Dilution Impact: Following the option grants, the total fully diluted share count increased to 34,735,053 shares.
- Plan Capacity: Verify the remaining shares available for future grants under the amended 2014 Plan.